TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Home-based Intervention to Improve the Diet Quality of Preschoolers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Speak English or Spanish~* Have a child between 2- 5 years of age~* Live with their child most of the time~* Have a phone that is able to video-record~* Be willing to have evening meals video recorded in the home~Exclusion Criteria:~\*Has a diagnosed feeding disorder, dietary restrictions, or medical condition that impacts how they feed their child.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Feeding, Healthy Eating (Type: EXPERIMENTAL): The experimental arm will receive three home over the first three months of the intervention.Visits will be conducted by a community health worker (CHW) trained in Motivational Interviewing. The home visits will include video-feedback on a meal; in-home cooking demonstrations; tailored text-messages, and mailed materials. During the last three months of the intervention, CHW will conduct monthly phone calls, together with mailed materials and text messages. The intervention will be tailored for families based on the child's appetitive traits and eating behaviors.
- Reading and Readiness (Type: ACTIVE_COMPARATOR): The Reading and Readiness group will receive information on school readiness promotion. Materials will be adapted and delivered by the community health worker (CHW) with a similar dose and schedule as the intervention group (three home visits and three phone calls). During the home visits, the CHW will show a video that models early childhood caregiver-child activities and demonstrates simple methods to interact with their children. They will also send a video of themselves reading with a child, receive text-messages based on these materials as well as the print materials during the last three months of the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine for Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18;~2. Diagnosis of Diabetes Mellitus (Fasting Plasma Glucose \> 126 mg/dL and/or HbA1C \>6.5%);~3. Distal symmetric pain in lower extremities with duration of more than 3 months;~4. Presence of either numbness or at least 1 sensory disturbance (increased or decreased sensitivity) in the feet.~5. Spontaneous pain with intensity of ≥ 4 on 0-10 Numerical Rating Scale (NRS).~Exclusion Criteria:~1. Not giving consent to participate in the study;~2. Unable to complete self-report pain questionnaire;~3. History of moderate to severe renal or liver failure;~4. History of other central or peripheral neurologic disorders;~5. History of cardiac arrhythmias;~6. Contraindication to intravenous lidocaine;~7. Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal saline infusion then lidocaine infusion (Type: PLACEBO_COMPARATOR): Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine \[5mg/kg\] over a 40 minute period.
- Lidocaine infusion, then normal saline infusion (Type: ACTIVE_COMPARATOR): Intravenous infusion of lidocaine \[5mg/kg\] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* In overall general good health.~* Females can enter and participate in this study if they are of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or if of childbearing potential, has a negative pregnancy test (urine) at screening and agrees to use GSK stipulated contraceptive methods.~* Must be newly diagnosed with a first recognized episode of GH at the time of the Screening Visit or within 3 months prior to the Screening Visit.~Exclusion criteria:~* Known or suspected to be immunocompromised (e.g., subjects receiving immunosuppressive therapy or chemotherapy for malignancy, or are seropositive for HIV).~* Received an investigational drug in the 30 days prior to the study.~* Receiving systemic antiviral or immunomodulatory treatments.~* Must not have received systemic antiviral treatments (e.g., valaciclovir, Famvir (famciclovir), acyclovir, lysine) within 3 days of starting study drug or immunomodulatory treatments in the 30 days before starting study drug.~* Clinically significant impaired renal function as defined by a creatinine clearance \<30 ml/min, calculated using the Cockcroft-Gault formula.~* Clinically significant impaired hepatic function defined as an ALT (alanine transaminase) level \> 5 times the normal upper limit.~* Subjects with active liver disease.~* Known to be hypersensitive to acyclovir, famciclovir, ganciclovir or any component of valaciclovir formulations.~* Known resistance to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir or valganciclovir.~* Subjects with malabsorption or vomiting syndrome or other gastrointestinal dysfunction that might impair drug pharmacokinetics.~* Women contemplating pregnancy within the duration of the study drug dosing period.~* Women who are pregnant and/or nursing mothers~* Current history of alcohol or drug abuse.~* Received suppressive (daily) therapy for genital herpes prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valaciclovir (Type: EXPERIMENTAL): Participants received double blinded treatment of oral dose of Valacyclovir 1 g given as 2 x 500 mg caplets QD for 6 months (24 weeks).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received double blinded treatment of oral dose of matching placebo to Valacyclovir 1 gram (g) given as 2 x 500 milligram (mg) caplets once daily (QD) for 6 months (24 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Meet criteria for the diagnosis of allergic asthma~* Be between the ages of 18 to 65 years~* Have a normal chest X-ray within 2 years of screening~Exclusion Criteria:~* Need daily controller medication for asthma~* History of hypersensitivity to the study drug or to drugs with similar chemical structures or to any ingredients, including excipients of the study medication or drugs related to omalizumab (e.g., monoclonal antibodies, polyclonal gamma globulin)~* Have a documented medical history of anaphylaxis~* Have lung disease other than mild allergic asthma~* Have taken other investigational drugs within 30 days or 5 half-lives prior to the screening visit, whichever is longer~* Are unable or unwilling to comply with study procedures and visits~* Are pregnant or lactating~* Have significant medical illness other than asthma, including malignancies, parasitic infections, immune system disorders, and thrombocytopenia~* Have been treated with omalizumab within 12 months prior to screening~* Currently smoke or have a history of smoking more than 10 pack-years~* Have a history of drug or alcohol abuse, which, in the judgment of the investigator, may put the subject at risk for being unable to participate fully in the study for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All patients who receive Humira for the treatment of psoriasis vulgaris or psoriatic arthritis not responding to conventional treatment will be evaluated. Eligible patients should be~* those not responding to at least one type of conventional systemic treatment (including ultraviolet therapy) who have skin lesions involving 10% of body surface area or~* patients with intractable eruptions of joint signs/symptoms.~Exclusion Criteria:~Contraindications according to the Package Insert include patients who have any of the following:~* serious infections~* tuberculosis~* a history of hypersensitivity to any ingredient of Humira~* demyelinating disease or a history of demyelinating disease~* congestive cardiac failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Humira (Type: None): Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 80 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and women age 18-72 years old who developed post-infectious diarrhea-predominant IBS (D-IBS)~* increased intestinal permeability on Lactulose/Mannitol permeability test~* able and willing to cooperate with the study~* \*absence of alcohol or NSAIDs ingestion for 2 weeks prior to inclusion into study and throughout the study duration~Exclusion Criteria:~* current participation in another research protocol or unable to give informed consent~* women with a positive urine pregnancy test or breastfeeding~* history of inflammatory bowel disease, lactose intolerance, and/or celiac sprue~* + hydrogen breath test for bacterial overgrowth~* + antiendomysial antibody titer~* use of nonsteroidal antinflammatory drug(NSAIDs) 2 weeks before or during the study~* known allergy to glutamine~* abdominal surgery except for removal of gallbladder, uterus, or appendix~* Abnormal blood urea nitrogen(BUN) and/or creatinine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Glutamine supplementation (Type: ACTIVE_COMPARATOR): Glutamine
- Placebo (Type: PLACEBO_COMPARATOR): Whey protein powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patient (18 years and older)~2. Knee arthroscopy not combined with open surgery.~3. Patients eligible for surgical treatment.~4. Patients are willing and able to continue study participation to ensure completion of all procedures and observations required by the study.~5. Written informed consent~Exclusion Criteria:~1. Diagnostic arthroscopy~2. Patients concomitantly treated systemically with strong concurrent CYP3A4 and P-gp-inhibitors, i.e. azole-antimycotics or HIV protease inhibitors.~3. Hypersensitivity to the active substance or to any of the excipients of study drug~4. Pregnant women or breast-feeding.~5. Hepatic disease associated with coagulopathy and clinically relevant bleeding risk~6. Known thrombophilia (hereditary or acquired)~7. Mandatory anticoagulation.~8. Known severe bleeding tendency~9. Clinically significant active bleeding.~10. Severe renal failure (GFR\<30mL/min/1.73m2)~11. Patients participating in another clinical trial.~12. Recent mayor surgery (6 to 12 weeks)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Oral Rivaroxaban 10 mg od for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): oral placebo od for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated moderate to advanced periodontitis (at least 4 teeth with a probing pocket depth (PD) \>4 mm, clinical attachment loss of at least 2 mm and radiographic evidence of bone loss)~* Presence of at least 12 scorable teeth (not including 3rd molars, teeth with orthodontic appliances, bridges, crowns or implants)~* Aggregatibacter actinomycetemcomitans-positive~Exclusion Criteria:~* Systemic illnesses (i.e. diabetes mellitus, cancer, HIV, bone metabolic diseases or disorders that compromise wound healing, radiation or immunosuppressive therapy)~* Pregnancy or lactation~* Systemic antibiotics taken within the previous two months~* Use of non-steroid anti-inflammatory drugs~* Confirmed or suspected intolerance to 5-nitroimidazole-derivatives or amoxicillin subgingival SRP or surgical periodontal therapy in the last year

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Protocol A (Type: EXPERIMENTAL): Antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the first, non-surgical phase of periodontal therapy (T1), and placebo during the second, surgical phase (T2)
- Protocol B (Type: ACTIVE_COMPARATOR): Placebo during the first, non-surgical phase of periodontal therapy (T1), and antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the second, surgical phase (T2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically- or cytologically-confirmed diagnosis of squamous NSCLC Stage IIIB with malignant effusion (fluid cytology demonstrating malignant cells required), Stage IV, or recurrent disease after definitive local therapy~* Candidate for primary treatment with cisplatin and gemcitabine~* Presence of measurable disease by RECIST~* Adequate organ function as defined by the following criteria: ECOG performance status of 0 or 1~Exclusion Criteria:~* Prior systemic treatment for Stage IIIB (with malignant effusion) or Stage IV NSCLC.~* One or more lung lesions with cavitation, or any lesion invading or abutting a major blood vessel as assessed by CT or MRI.~* History of hemoptysis \> ½ tsp (2.5 ml) of blood per day for a day or more within 1 week of study treatment, or Grade 3 or 4 hemoptysis within 4 weeks of study treatment~* NCI CTCAE Grade 3 hemorrhage from any cause within 4 weeks of study treatment~* Preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart.~* Untreated brain metastases.~* Need for therapeutic anticoagulation, regular use of aspirin (\> 325 mg/day), NSAID or other medications known to inhibit platelet function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AG-013736/Cisplatin/Gemcitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males in good general health and at least 50 years of age, with symptoms of moderate to severe Benign Prostatic Hyperplasia~Exclusion Criteria:~* Medical conditions that would confound the efficacy evaluation~* Medical conditions in which it would be unsafe to use an alpha-blocker~* Use of concomitant drugs that would confound the efficacy evaluation~* Use of concomitant drugs that would be unsafe with this alpha-blocker

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Silodosin (Type: EXPERIMENTAL): None
- Tamsulosin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female greater than 18 years of age;~* Previously met the preliminary criteria of the American Rheumatism Association (ARA) for the classification of the acute arthritis of primary gout;~* At least 2 gout flares in the year prior to the screening visit.~Exclusion Criteria:~* Acute gout flare within 2 weeks of the screening visit and during screening;~* Persistent chronic or active infections;~* History of an allergic reaction to allopurinol;~* History or presence of cancer within 5 years of the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 16.
- Rilonacept 160 mg (Type: EXPERIMENTAL): Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addressing Dementia Via Agitation-Centered Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.~* Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.~Exclusion Criteria:~* Patient has dementia predominantly of non-Alzheimer's type.~* Unable to comply with study procedures.~* Medically inappropriate for study participation in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- AXS-05 (Type: EXPERIMENTAL): AXS-05 tablets taken by mouth for 5 weeks.
- Bupropion (Type: ACTIVE_COMPARATOR): Bupropion tablets taken by mouth for 5 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets taken by mouth for 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Neurontin on Pain Management in the Acutely Burned Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All admitted patients with LOS expected to be \> 48 hours (usually burn injury \> 5%)~* \> 18 years of age~* Thermal injury to skin~Exclusion Criteria:~* Prisoners~* Pregnant or nursing women~* Children \<18 years of age~* Frostbite or non thermal injury to skin~* Renal insuffiency (creatinine clearance \< 60mL/min) or failure (on renal replacement)~* Expected length of stay \< 48 hours (this usually includes burn \<5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo
- Gabapentin (Type: EXPERIMENTAL): Gabapentin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete